A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524090-16-00

Enrollment

Registered

2026-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Brief summary

Type, frequency, and severity of side effects.

Detailed description

How BMS-986525 behaves in the body alone and in combination with nivolumab;, How disease responds to BMS-986525 alone or in combination with nivolumab.

Interventions

DRUGBMS-986525

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Type, frequency, and severity of side effects.	—

Secondary

Measure	Time frame
How BMS-986525 behaves in the body alone and in combination with nivolumab;, How disease responds to BMS-986525 alone or in combination with nivolumab.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 19, 2026